EP Patent

EP0395417A1 — Linear somatostatin analogues

Assigned to Tulane University · Expires 1990-10-31 · 36y expired

What this patent protects

Linear octapeptides which are somatastatin analogues have the formula: wherein A¹ to A⁸ may represent Ala, pyridyl-Ala, Leu, Ile, Val, Phe, Nle, Trp, beta-Nal, ortho- and para-­substutited Phe, 2,4-dichloro Phe, pentafluoro-Phe, Ser-R⁴ or Thr-R⁴; R¹ and R² independently rep…

USPTO Abstract

Linear octapeptides which are somatastatin analogues have the formula: wherein A¹ to A⁸ may represent Ala, pyridyl-Ala, Leu, Ile, Val, Phe, Nle, Trp, beta-Nal, ortho- and para-­substutited Phe, 2,4-dichloro Phe, pentafluoro-Phe, Ser-R⁴ or Thr-R⁴; R¹ and R² independently represents H, lower acyl or lower alkyl; R³ represents H, -NH₂ or lower alkyl; R⁴ represents nothing, a glycosyl residue or a carbohydrate. Also disclosed are pharmaceutical compositions containing the octapeptides, for inhibiting release of growth hormone, IGF-1, insulin and glucagon. A process for the preparation of the octapeptides is described.

Drugs covered by this patent

Patent Metadata

Patent number
EP0395417A1
Jurisdiction
EP
Classification
—
Expires
1990-10-31
Drug substance claim
No
Drug product claim
No
Assignee
Tulane University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.